DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/3b5e71/mergers_and_acquis) has announced the addition of the "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market" report to their offering.
Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy and highlights the key opportunities and challenges presented by both business models
On 26th January 2009, Pfizer announced plans to acquire Wyeth for $68 billion. Pfizer's CEO, Jeffrey B Kindler, insisted the deal would be different from the company's earlier mega-deals involving the acquisitions of Pharmacia (2002) and Warner-Lambert (2000) - the acquisition of Wyeth would provide a broad and diversified portfolio, rather than been focused on a single product or cost-cutting. Pfizer's strategy of growing its portfolio through a mega M&A deals follows the 2008 acquisitions of Millennium by Takeda and ImClone by Eli Lilly.
Some key findings from the report
- Significant industry consolidation will lead to a fundamental shift in the market dynamics across all major product categories.
- Since the beginning of 2006 a total of seven deals have been agreed with total transaction fees in excess of US$10 billion.
- It appears likely that the mega-M&A wave started by the 3 deals in Q109 is not yet finished.
- A handful of major players will follow in the footsteps of Pfizer and enter into major M&A transactions involving a significant step change in market shares and industry consolidation.
- Abbott Labs
- Bayer/Schering AG
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eisai/MGI Pharma
- Eli Lilly
- Johnson & Johnson
- Merck KGaA/Serono
- Novo Nordisk
- Nycomed/Altana Pharma
- Teva/Barr Labs
- UCB/Schwarz Pharma
For more information visit http://www.researchandmarkets.com/research/3b5e71/mergers_and_acquis
Source: Spectra Intelligence
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
INDUSTRY KEYWORDS: Health Pharmaceutical